About Bolt Biotherapeutics, Inc.
https://www.boltbio.comBolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system.
CEO
William P. Quinn
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-06-09 | Reverse | 1:20 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
HAWKEYE CAPITAL MANAGEMENT, LLC
Shares:415.04K
Value:$2.68M
BLACKROCK INC.
Shares:267.07K
Value:$1.72M
PICTET ASSET MANAGEMENT LTD
Shares:186.43K
Value:$1.2M
Summary
Showing Top 3 of 31
About Bolt Biotherapeutics, Inc.
https://www.boltbio.comBolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $2.17M ▲ | $9.58M ▼ | $-7.14M ▲ | -329.37% ▲ | $-3.72 ▲ | $-6.85M ▲ |
| Q2-2025 | $1.8M ▲ | $11.01M ▼ | $-8.56M ▲ | -474.56% ▲ | $-4.46 ▼ | $-8.86M ▲ |
| Q1-2025 | $1.22M ▲ | $13.34M ▼ | $-11.04M ▲ | -903.44% ▼ | $-0.29 ▲ | $-11.72M ▲ |
| Q4-2024 | $0 ▼ | $15.24M ▼ | $-15.94M ▼ | 0% ▲ | $-0.42 ▼ | $-15.51M ▲ |
| Q3-2024 | $1.14M | $17.58M | $-15.18M | -1.33K% | $-0.4 | $-16M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $31.91M ▼ | $65.05M ▼ | $32.95M ▼ | $32.1M ▼ |
| Q2-2025 | $34.77M ▼ | $75.5M ▼ | $36.66M ▼ | $38.84M ▼ |
| Q1-2025 | $38.84M ▼ | $85.86M ▼ | $39.05M ▼ | $46.81M ▼ |
| Q4-2024 | $47.32M ▼ | $99.63M ▼ | $42.43M ▲ | $57.2M ▼ |
| Q3-2024 | $53.8M | $109.33M | $37.3M | $72.03M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-7.14M ▲ | $-9.73M ▼ | $17.88M ▲ | $0 ▼ | $8.15M ▲ | $-9.8M ▼ |
| Q2-2025 | $-8.56M ▲ | $-9.6M ▲ | $10.79M ▼ | $14K ▲ | $1.21M ▲ | $-9.6M ▲ |
| Q1-2025 | $-11.04M ▲ | $-13.37M ▲ | $14.55M ▲ | $0 ▼ | $1.19M ▲ | $-13.37M ▲ |
| Q4-2024 | $-15.94M ▼ | $-14.43M ▼ | $12.23M ▼ | $29K ▲ | $-2.17M ▼ | $-14.43M ▼ |
| Q3-2024 | $-15.18M | $-13.97M | $17.14M | $0 | $3.17M | $-14.01M |
CEO
William P. Quinn
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-06-09 | Reverse | 1:20 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
HAWKEYE CAPITAL MANAGEMENT, LLC
Shares:415.04K
Value:$2.68M
BLACKROCK INC.
Shares:267.07K
Value:$1.72M
PICTET ASSET MANAGEMENT LTD
Shares:186.43K
Value:$1.2M
Summary
Showing Top 3 of 31